SCHEMBL3141179

SCHEMBL3141179

O=C(c1cc(F)cc(F)c1)N1CCCC(c2nc(Oc3cccc(F)c3)no2)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ RAB9A P51151 2/20 0.60
▸ POLB P06746 1/20 0.54
▸ GRM5 P41594 2/20 0.53
▸ CLPP Q16740 1/20 0.53
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ ATM Q13315 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ HSD11B1 P28845 1/20 0.50
▸ NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141171 1.00 L3MBTL1 (0.63) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3137416 0.95 L3MBTL1 (0.69) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3137399 0.95 L3MBTL1 (0.69) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3130199 0.93 L3MBTL1 (0.63) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3130211 0.93 L3MBTL1 (0.63) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3140639 0.93 GRM5 (0.63) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3146200 0.93 GRM5 (0.63) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3141460 0.93 L3MBTL1 (0.58) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3141476 0.93 L3MBTL1 (0.58) L3MBTL1RAB9APOLBGRM5CLPP
SCHEMBL3137406 0.92 L3MBTL1 (0.60) L3MBTL1RAB9APOLBGRM5CLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2010-01-07 — — US claimed
EP-1896464-A1 NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2008-03-12 — — EP claimed
WO-2006129199-A1 NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-12-07 — — WO claimed
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM5, GRM1, GRIK5 L3MBTL1 3297/4885RAB9A 1083/4885POLB 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback